Thrombin Mutant W215A/E217A Treatment Improves Neurological Outcome and Reduces Cerebral Infarct Size in a Mouse Model of Ischemic Stroke

BACKGROUND AND PURPOSE: Treatment of ischemic stroke by activation of endogenous plasminogen using tissue plasminogen activator (tPA) is limited by bleeding side effects. In mice, treatment of experimental ischemic stroke with activated protein C (APC) improves outcomes; however, APC also has bleedi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Berny-Lang, Michelle A., Hurst, Sawan, Tucker, Erik I., Pelc, Leslie A., Wang, Ruikang K., Hurn, Patricia D., Di Cera, Enrico, McCarty, Owen J.T., Gruber, András
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3115697/
https://ncbi.nlm.nih.gov/pubmed/21512172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/STROKEAHA.110.603811
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares